US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,316.40

+27.392.12%

Number of Gainers:10

Number of Losers:9

Number of Flat:1

PE:- -

High:1,318.99

Open:1,294.01

Low:1,294.01

Close:1,288.98

Loading ...

Ibio Inc: Qtrly EPS From Cont Ops -$0.49

THOMSON REUTERS

Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13

Press Release: iBio Reports Fiscal Third Quarter 2025 Financial Results

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Astrazeneca Asthma Treatment Study Meets Primary Endpoints

MT Newswires Live

FACTBOX-European companies cut jobs in response to slowing economy

Investors in Abbott Laboratories (NYSE:ABT) have seen notable returns of 52% over the past five years

Simply Wall St.

BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma

Who’s backing who? Every newspaper’s pick for prime minister

The Sydney Morning Herald

Arvinas price target lowered to $16 from $32 at Barclays

Where Will Viking Therapeutics Be in 3 Years?

3 No-Brainer Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought in May

J&J-backed HistoSonics explores sale at $2.5 billion valuation, FT reports

BRIEF-JNJ-Backed Histosonics Is Pursuing A Sale After Fielding Takeover Bids, Seeking A Valuation Of More Than $2.5 Billion - FT

Merck & Co., Inc. (MRK): Jim Cramer Agrees – “Merck’s A Good Company”

Lakeland Industries Inc. Announces Cash Dividend of $0.03 Per Share for Second Quarter 2026

Lakeland Fire + Safety Declares Cash Dividend for Second Quarter 2026

Hologic Announces Financial Results for Second Quarter of Fiscal 2025

GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update

Moderna (MRNA) Receives a Hold from RBC Capital

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4568/news?page=11"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1316.3655,"timestamp":1747333143869,"preClose":1288.9788,"halted":0,"volume":71546120,"delay":0,"changeRate":0.021247,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":27.386719,"latestTime":"05-15 14:19:04 EDT","open":1294.0085,"high":1318.9875,"low":1294.0085,"amount":2946452150.345434,"amplitude":0.019379,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1747339200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.481117,"peRate":20.661892,"turnoverRate":0.004608,"increases":10,"decrements":9,"flats":1,"marketCap":1084959545917,"floatMarketCap":1067122917162.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1318.9875,"amplitude":0.019379,"preClose":1288.9788,"low":1294.0085,"pbRate":"3.481117","latestPrice":1316.3976,"volume":71547154,"delay":0,"open":1294.0085,"prevYearClose":1274.8187,"prevWeekClose":1327.5806,"prevMonthClose":1374.5028,"prevQuarterClose":1427.887,"fiveDayClose":1336.712,"twentyDayClose":1326.3606,"sixtyDayClose":1406.0599,"secType":"PLATE","market":"US","turnoverRate":0.004608,"peRate":20.661892,"marketCap":1084959545917,"floatMarketCap":1067122917162.5,"timestamp":1747333145587,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":10,"down":9,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:11,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532784813","title":"Ibio Inc:  Qtrly EPS From Cont Ops -$0.49","url":"https://stock-news.laohu8.com/highlight/detail?id=2532784813","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532784813?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:00","pubTimestamp":1746187201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nTUA1L8YL1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBIO","BK4139","BK4568"],"gpt_icon":0},{"id":"2532884878","title":"Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13","url":"https://stock-news.laohu8.com/highlight/detail?id=2532884878","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532884878?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:00","pubTimestamp":1746187200,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., May 02, 2025  -- Vaxart, Inc. today announced it will provide a business update and report financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET.The conference call can be accessed using the following information:. Webcast: Click hereDate: Tuesday, May 13, 2025 – 4:30 p.m. ETDomestic:  407-0832International:  689-8433Conference ID: 13753354. This press release was published by a CLEAR Verified individual.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vaxart-host-first-quarter-2025-120000093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HST","BK4588","BK4139","VXRT","BK4585","BK4218","BK4568","BK4181"],"gpt_icon":0},{"id":"2532485688","title":"Press Release: iBio Reports Fiscal Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2532485688","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532485688?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:00","pubTimestamp":1746187200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May 02, 2025  -- iBio, Inc. , today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress.\"During the third quarter we were able to broaden our access to investors given our move to Nasdaq and subsequently in April, strengthened our financial position with a $6.2 million warrant-inducement equity raise, positioning us for continued growth and keeping us on track for regulatory submission of IBIO-600 in 2026,\" said Martin Brenner, Ph.D., DVM, iBio's Chief Executive Officer and Chief Scientific Officer. \"At the same time, we made significant strides in our pipeline, with promising non-human primate data for IBIO-600 and the in-licensing of a first-in-class Activin E antibody, two antibodies we truly believe are bringing us closer to fulfilling our mission of delivering transformative therapies to patients suffering from cardiometabolic diseases and obesity.\". Fiscal Third Quarter 2025 & Recent Corporate Updates:.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","IBIO","NQmain"],"gpt_icon":0},{"id":"2532482118","title":"Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2532482118","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532482118?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:00","pubTimestamp":1746187200,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., May 02, 2025  -- Ocugen, Inc.  , a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s first quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, May 9, 2025.Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:. Dial-in Numbers:  715-9871 for U.S. callers and  307-1963 for international callersConference ID: 1773288Webcast: Available on theeventssection of the Ocugeninvestor site. A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugeninvestor site.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ocugen-host-conference-call-friday-120000294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HST","BK4585","ET","BK4181","BK4561","BK4144","BK4139","BK4218","BK4581","BK4568","BK4590","BK4588","OCGN","BK4563"],"gpt_icon":0},{"id":"2532810122","title":"Astrazeneca Asthma Treatment Study Meets Primary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2532810122","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532810122?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:42","pubTimestamp":1746186167,"startTime":"0","endTime":"0","summary":"Astrazeneca (AZN) said Friday that its fixed-dose triple-combination therapy Breztri Aerosphere met all primary endpoints in a phase 3 trial to treat asthma.The British pharmaceutical company said the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765992.SGD","LU0109394709.USD","LU2462157665.USD","AZN","LU2236285917.USD","LU2456880835.USD","BK4588","BK4568","BK4007","BK4585","LU1829250122.USD","LU0889565916.HKD","LU2417539215.USD"],"gpt_icon":0},{"id":"2532810559","title":"FACTBOX-European companies cut jobs in response to slowing economy","url":"https://stock-news.laohu8.com/highlight/detail?id=2532810559","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532810559?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:39","pubTimestamp":1746185959,"startTime":"0","endTime":"0","summary":"FACTBOX-European companies cut jobs in response to slowing economyAdds LVMH, STMicro, updates Volkswagen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nL8N3RA0YD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4588","BNTX","BK4139","BK4585","BK4568","BK4535","BK4548"],"gpt_icon":0},{"id":"2532817591","title":"Investors in Abbott Laboratories (NYSE:ABT) have seen notable returns of 52% over the past five years","url":"https://stock-news.laohu8.com/highlight/detail?id=2532817591","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532817591?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:00","pubTimestamp":1746183617,"startTime":"0","endTime":"0","summary":"The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up more than the market average. But Abbott Laboratories  has fallen short of that second goal, with a share price rise of 39% over five years, which is below the market return. On a brighter note, more newer shareholders are probably rather content with the 24% share price gain over twelve months.With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share  with the share price movement.During five years of share price growth, Abbott Laboratories achieved compound earnings per share  growth of 31% per year","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investors-abbott-laboratories-nyse-abt-110017872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0009355771.USD","BK4585","LU1023059063.AUD","SG9999002232.USD","SGXZ23171101.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BK4568","LU0170899867.USD","LU2112291526.USD","IE00B4R5TH58.HKD","LU2237957902.USD","SG9999004303.SGD","BK4211","BK4581","ISBC","LU1691799644.USD","LU1989763427.SGD","LU1989763690.USD","SG9999002224.SGD","LU0234572021.USD","BK4588","LU1061106388.HKD","LU0122379950.USD","LU2133065610.SGD","LU0266013472.USD","LU2089984988.USD","LU2468319806.SGD","IE00B2B36J28.USD","LU1914381329.SGD","BK4566","LU0868494617.USD","LU1057294990.SGD","BK4082","IE0002141913.USD","BK4504","NYSE","ABT","LU1721429741.USD","IE00BJJMRZ35.SGD","LU1721429402.USD","BK4592","LU2237957811.SGD","BK4533"],"gpt_icon":0},{"id":"2532810675","title":"BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma","url":"https://stock-news.laohu8.com/highlight/detail?id=2532810675","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532810675?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:00","pubTimestamp":1746183600,"startTime":"0","endTime":"0","summary":"KALOS and LOGOS were replicate, randomized, double-blind trials designed to investigate BREZTRI as a potential treatment for asthma.1,2 The trials evaluated the efficacy and safety of BREZTRI versus maintenance treatment with ICS/LABA in adults and adolescents with uncontrolled asthma.1,2. Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: \"We are excited by the positive results from the KALOS and LOGOS trials, which demonstrate that BREZTRI could help improve the lives of the millions of patients living with asthma. These asthma data build on the well-established profile of BREZTRI in COPD, and we look forward to sharing with regulatory authorities to bring this important medicine to a wider group of patients.\". There were no new safety or tolerability signals identified for BREZTRI in KALOS or LOGOS.Full results from the two Phase III trials will be shared with regulatory authorities and presented at an upcoming medical meeting.BREZTRI is an inhaled tri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/breztri-met-primary-endpoints-kalos-110000396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["III","LU1829250122.USD","LU2236285917.USD","BK4007","AZN","BK4134","LU2417539215.USD","LU2456880835.USD","BK4585","BK4588","CDC","LU0109394709.USD","BK4568","LU0320765992.SGD","LU0889565916.HKD","LU2462157665.USD"],"gpt_icon":0},{"id":"2532501819","title":"Who’s backing who? Every newspaper’s pick for prime minister","url":"https://stock-news.laohu8.com/highlight/detail?id=2532501819","media":"The Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532501819?lang=en_us&edition=fundamental","pubTime":"2025-05-02 17:00","pubTimestamp":1746176400,"startTime":"0","endTime":"0","summary":"It’s tradition for Australia’s biggest newspapers to editorially endorse a party in print and online the day before Australians head to the polls.On Friday, a slim majority of newspapers, led by News ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.smh.com.au/business/companies/who-s-backing-who-every-newspaper-s-pick-for-prime-minister-20250501-p5lvup.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smh_stock","symbols":["ABT","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","BK4504","IE00BJJMRZ35.SGD","BK4581","LU2112291526.USD","LU2089984988.USD","LU1691799644.USD","LU0868494617.USD","LU1721429741.USD","XKO.AU","LU2133065610.SGD","XJO.AU","BK4568","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU2468319806.SGD","BK4566","LU2237957811.SGD","LU0266013472.USD","LU0234572021.USD","LU2237957902.USD","LU0170899867.USD","BK4588","IE0009355771.USD","LU1989763427.SGD","SG9999002224.SGD","XAO.AU","IE00B2B36J28.USD","BK4585","IE0002141913.USD","LU1914381329.SGD","LU1721429402.USD","LU1989763690.USD","SG9999002232.USD","BK4533","BK4082","LU0122379950.USD","SG9999004303.SGD","SGXZ23171101.USD","BK4592","LU1057294990.SGD","LU1023059063.AUD"],"gpt_icon":0},{"id":"2532890674","title":"Arvinas price target lowered to $16 from $32 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2532890674","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532890674?lang=en_us&edition=fundamental","pubTime":"2025-05-02 16:50","pubTimestamp":1746175849,"startTime":"0","endTime":"0","summary":"Barclays lowered the firm’s price target on Arvinas (ARVN) to $16 from $32 and keeps an Overweight rating on the shares. The firm says Pfizer reduc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arvinas-price-target-lowered-to-16-from-32-at-barclays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arvinas-price-target-lowered-to-16-from-32-at-barclays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SG9999013999.USD","BK4581","SG9999001176.USD","LU0225771236.USD","LU0985481810.HKD","BK4599","LU0225284248.USD","IE00BLSP4239.USD","ARVN","LU1023059063.AUD","LU1057294990.SGD","LU0321505439.SGD","SG9999002224.SGD","SG9999003800.SGD","BK4007","LU0234572021.USD","BK4592","LU1883839398.USD","BK4588","LU0306807586.USD","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","LU1066053197.SGD","SGXZ57979304.SGD","LU1894683264.USD","IE000M9KFDE8.USD","LU0122379950.USD","IE00BBT3K403.USD","LU0170899867.USD","LU0058720904.USD","IE00B19Z3581.USD","LU0868494617.USD","LU0306806265.USD","LU1066051498.USD","BK4534","BK4568","SG9999011175.SGD","IE0002270589.USD","BK4533","LU1894683348.USD","LU0456855351.SGD","LU0289739699.SGD","BK4585","SG9999001176.SGD","LU0321505868.SGD","BK4550","SG9999002232.USD"],"gpt_icon":0},{"id":"2532894454","title":"Where Will Viking Therapeutics Be in 3 Years?","url":"https://stock-news.laohu8.com/highlight/detail?id=2532894454","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532894454?lang=en_us&edition=fundamental","pubTime":"2025-05-02 16:20","pubTimestamp":1746174000,"startTime":"0","endTime":"0","summary":"Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/02/where-will-viking-therapeutics-be-in-3-years/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4139","LU0321505439.SGD","SG9999003800.SGD","VKTX","IE00BBT3K403.USD","BK4534","IE0002270589.USD","LU0306807586.USD","LU0225771236.USD","LU0058720904.USD","LU0456855351.SGD","BK4592","LU0289739699.SGD","LU1066051498.USD","LU0306806265.USD","LU1894683348.USD","LU0321505868.SGD","SG9999002232.USD","LU0234572021.USD","SG9999011175.SGD","BK4581","BK4599","LU0985481810.HKD","LU0868494617.USD","LU1023059063.AUD","LU1894683264.USD","LU1883839398.USD","IE000M9KFDE8.USD","BK4585","BK4568","BK4007","IE00B19Z3581.USD","SG9999001176.SGD","BK4550","IE00BLSP4239.USD","LU0122379950.USD","BK4533","LU0170899867.USD","LU0225284248.USD","LU1057294990.SGD","SG9999013999.USD","SG9999001176.USD","SG9999002224.SGD","IE00BLSP4452.SGD","LU1066053197.SGD","IE00B19Z3B42.SGD","SGXZ57979304.SGD","BK4588"],"gpt_icon":1},{"id":"2532899973","title":"3 No-Brainer Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought in May","url":"https://stock-news.laohu8.com/highlight/detail?id=2532899973","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532899973?lang=en_us&edition=fundamental","pubTime":"2025-05-02 15:51","pubTimestamp":1746172260,"startTime":"0","endTime":"0","summary":"Three supercharged income stocks -- sporting an average yield of 8.63% -- are perfectly positioned to fatten investors' pocketbooks.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/02/3-ultra-high-yield-dividend-stocks-to-buy-in-may/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0289739699.SGD","US2Y.BOND","SG9999002232.USD","US7Y.BOND","BK4588","PFE","LU1023059063.AUD","LU1894683264.USD","SG9999003800.SGD","BK4585","BK4599","LU0170899867.USD","SGXZ57979304.SGD","SG9999002224.SGD","IE00B19Z3581.USD","IE0002270589.USD","BDC","BK4550","LU0868494617.USD","US6M.BOND","BK4568","LU0225771236.USD","LU0456855351.SGD","LU1057294990.SGD","LU0122379950.USD","US12M.BOND","SG9999011175.SGD","US30Y.BOND","LU0225284248.USD","LU1066051498.USD","LU0058720904.USD","IE00B19Z3B42.SGD","BK4592","SG9999001176.USD","US5Y.BOND","LU1066053197.SGD","BK4534","LU0306806265.USD","BK4148","BK4581","IE00BBT3K403.USD","BK4007","BK4533","US3Y.BOND","IE00BLSP4239.USD","LU0234572021.USD","IE00BLSP4452.SGD","LU0306807586.USD","US10Y.BOND","LU0321505868.SGD"],"gpt_icon":1},{"id":"2532657118","title":"J&J-backed HistoSonics explores sale at $2.5 billion valuation, FT reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2532657118","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532657118?lang=en_us&edition=fundamental","pubTime":"2025-05-02 12:13","pubTimestamp":1746159235,"startTime":"0","endTime":"0","summary":"J&J-backed HistoSonics explores sale at $2.5 billion valuation, FT reportsMay 2  - HistoSonics, a medical technology company backed by Johnson & Johnson JNJ.N, is exploring a potential sale after receiving multiple takeover approaches, the Financial Times reported on Friday, citing people familiar with the matter.The company is seeking a valuation of more than $2.5 billion, the report said.  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nL4N3RA0F8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051225.USD","IE0034235303.USD","LU1894683348.USD","IE00BLSP4239.USD","LU2430703178.SGD","LU2430703095.HKD","LU1074936037.SGD","IE00BFTCPJ56.SGD","IE00B19Z3B42.SGD","BK4534","BK4592","LU0234572021.USD","IE00BDGV0183.EUR","BK4007","BK4550","JNJ","IE00BJJMRZ35.SGD","IE00B19Z3581.USD","LU0985320562.USD","BK4559","LU0320765646.SGD","LU1718418525.SGD","LU1778281490.HKD","LU1244550577.SGD","LU1066051811.HKD","LU2112291526.USD","LU2129689605.HKD","BK4568","IE00BBT3K403.USD","LU1506573853.SGD","IE00BJT1NW94.SGD","LU0098860793.USD","LU0345770993.USD","IE00B3T34201.USD","LU2089984988.USD","LU0795875169.SGD","SG9999002224.SGD","LU0882574055.USD","IE00BGHQF631.EUR","LU1244550221.USD","LU0203345920.USD","LU1267930813.SGD","IE00BVYPNW00.USD","LU0114720955.EUR","LU2129689431.USD","LU0889566641.SGD","LU1732800096.USD","LU0912757837.SGD","BK4533","LU0345770308.USD"],"gpt_icon":0},{"id":"2532865101","title":"BRIEF-JNJ-Backed Histosonics Is Pursuing A Sale After Fielding Takeover Bids, Seeking A Valuation Of More Than $2.5 Billion - FT","url":"https://stock-news.laohu8.com/highlight/detail?id=2532865101","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532865101?lang=en_us&edition=fundamental","pubTime":"2025-05-02 12:06","pubTimestamp":1746158772,"startTime":"0","endTime":"0","summary":"BRIEF-JNJ-Backed Histosonics Is Pursuing A Sale After Fielding Takeover Bids, Seeking A Valuation Of More Than $2.5 Billion - FTMay 2 (Reuters) - JNJ-BACKED HISTOSONICS IS PURSUING A SALE AFTER FIELDI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nFWN3R93KS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","JNJ","LU0882574055.USD","LU1506573853.SGD","LU0345770308.USD","LU1057294990.SGD","LU2089984988.USD","LU0289739699.SGD","LU2133065610.SGD","LU2430703178.SGD","LU1066051498.USD","LU1244550577.SGD","IE0034235303.USD","LU2602419157.SGD","LU1674673428.USD","IE00BFTCPJ56.SGD","BK4534","LU2347655156.SGD","LU1732800096.USD","IE00BLSP4452.SGD","BK4533","LU1066053197.SGD","LU2129689605.HKD","LU1074936037.SGD","LU0098860793.USD","LU0203345920.USD","LU2468319806.SGD","LU0122379950.USD","IE00BLSP4239.USD","LU1732799900.SGD","LU1914381329.SGD","SG9999002232.USD","LU1221951046.USD","LU0792757196.USD","LU1244550494.USD","LU1929549753.HKD","LU0640476718.USD","LU1894683264.USD","LU1244550221.USD","LU2592432038.USD","IE00B4R5TH58.HKD","BK4568","LU2129689514.USD","LU0234572021.USD","IE00BJT1NW94.SGD","LU1894683348.USD","LU1674673691.USD","LU1267930813.SGD","BK4504","LU0320765646.SGD"],"gpt_icon":0},{"id":"2532341058","title":"Merck & Co., Inc. (MRK): Jim Cramer Agrees – “Merck’s A Good Company”","url":"https://stock-news.laohu8.com/highlight/detail?id=2532341058","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532341058?lang=en_us&edition=fundamental","pubTime":"2025-05-02 05:23","pubTimestamp":1746134620,"startTime":"0","endTime":"0","summary":"We recently published Jim Cramer’s Surprised About US Travel As He Discusses These 18 Stocks. In this article, we are going to take a look at where Merck & Co., Inc.  stands against other stocks that Jim Cramer discussed.In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer commented on the growing amount of stock buybacks and how the buybacksduring April-May were the third best historically of the year. “Well, I’ll tell ya, the banks are the ones that are going to do it. They’re gonna start it and the banks have an appetite for their stock that is crazy,” he said.Merck & Co., Inc.  is one of the largest pharmaceutical companies in the world. It is a regular feature of Cramer’s morning show. In his previous appearances, the TV host has lamented that China is cre","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-co-inc-mrk-jim-212340697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE000M9KFDE8.USD","IE00BN8TJ469.HKD","LU1983299246.USD","LU0211331839.USD","LU0070302665.USD","IE00B2B36J28.USD","LU0321505868.SGD","LU0006306889.USD","LU1061106388.HKD","LU0321505439.SGD","LU1093756168.USD","LU1066051811.HKD","LU1116320901.HKD","LU0058720904.USD","SG9999003800.SGD","LU0203345920.USD","LU1035773651.USD","LU2361044949.HKD","LU1934455863.HKD","LU0234572021.USD","LU1989772840.SGD","BK4516","LU0861579265.USD","IE0002141913.USD","LU0208291251.USD","MRK","LU2468319806.SGD","LU0306807586.USD","LU1974910355.USD","LU0320765646.SGD","LU0965508806.USD","BK4007","LU2023250843.SGD","LU0203347892.USD","SG9999002232.USD","LU1066051498.USD","IE00BSNM7G36.USD","LU0225771236.USD","LU0106261372.USD","LU1699723380.USD","LU2106854487.HKD","LU1069347547.HKD","LU0985320562.USD","LU1162221912.USD","SG9999001176.SGD","BK4599","LU0985481810.HKD","BK4568","LU1037948897.HKD"],"gpt_icon":1},{"id":"2532836860","title":"Lakeland Industries Inc. Announces Cash Dividend of $0.03 Per Share for Second Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2532836860","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532836860?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:22","pubTimestamp":1746130959,"startTime":"0","endTime":"0","summary":"Lakeland Industries Inc. announced that its Board of Directors has declared a cash dividend of $0.03 per share for the fiscal second quarter of 2026. The dividend is set to be paid on May 22, 2025, to stockholders of record as of May 15, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakeland Industries Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nNDL9L4639:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","IE00B19Z4B17.USD","BK4202","BK4568","IE0031619046.USD","IE00B66KJ199.SGD","LAKE"],"gpt_icon":0},{"id":"2532629839","title":"Lakeland Fire + Safety Declares Cash Dividend for Second Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2532629839","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532629839?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:05","pubTimestamp":1746129900,"startTime":"0","endTime":"0","summary":"HUNTSVILLE, Ala., May 01, 2025  -- Lakeland Industries, Inc.  , a leading global manufacturer of protective clothing and apparel for industry, healthcare and first responders, today announced that its Board of Directors declared a cash dividend for its fiscal second quarter of 2026 of $0.03 per share. The dividend will be paid on May 22, 2025, to stockholders of record as of May 15, 2025.This press release contains \"forward-looking statements\" as that phrase is defined in the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, which address Lakeland's expectations of sources or uses for capital or which express the Company's expectation for the future with respect to financial performance or operating strategies, including statements regarding payment of a quarterly dividend, can be identified as forward-looking statements. Forward-looking statements involve risks, uncertainties and assumptions as described from time to time in P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lakeland-fire-safety-declares-cash-200500759.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z4B17.USD","BK4568","BK4202","IE00B7SZL793.SGD","IE00B66KJ199.SGD","IE0031619046.USD","LAKE"],"gpt_icon":0},{"id":"2532831555","title":"Hologic Announces Financial Results for Second Quarter of Fiscal 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2532831555","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532831555?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:01","pubTimestamp":1746129660,"startTime":"0","endTime":"0","summary":"– Revenue of $1,005.3 Million Slightly Exceeds Guidance –。– Company Reports GAAP Diluted EPS of ; Non-GAAP Diluted EPS of $1.03 at High End of Guidance –。– Company Maintains Annual Revenue Guidance, Lowers Guidance for GAAP and Non-GAAP EPS –。MARLBOROUGH, Mass., May 01, 2025----Hologic, Inc.  announced today the Company’s financial results for the fiscal second quarter ended March 29, 2025.\"We delivered on our financial commitments in the second quarter,\" said Stephen P. MacMillan, the Company’s Chairman, President and Chief Executive Officer. \"Both revenue and non-GAAP EPS finished at the high ends of our guidance ranges, driven by our diagnostics and skeletal businesses, strong profitability, share buybacks and a slightly lower tax rate.\". Total organic revenue excluding COVID-19, the divested blood screening and SSI businesses, and the acquired Endomagnetics and Gynesonics businesses decreased , or  on a constant currency basis.Excluding COVID-19 revenue, organic diagnostics sales g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hologic-announces-financial-results-second-200100036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0823416689.USD","LU1923622614.USD","LU2125909593.SGD","BK4568","BK4548","LU2433249047.HKD","BK4588","LU1923623000.USD","LU2125909247.SGD","BK4585","LU1951200564.SGD","BK4551","BNTX","BK4139","BK4231","LU1951198990.SGD","HOLX","BK4535","BK4080","ROIC","BK4082"],"gpt_icon":0},{"id":"2532839661","title":"GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2532839661","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532839661?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:00","pubTimestamp":1746129600,"startTime":"0","endTime":"0","summary":"COVID-19 vaccine program progressing with additional data evaluating GEO-CM04S1 as booster to mRNA vaccines in healthy adults expected in second quarter of 2025. Clinical evaluation of GEO-MVA, vaccine candidate for protection against Mpox and Smallpox, expected to initiate in second half of 2025. \"Despite the recent and unexpected termination of our Project NextGen award by BARDA, our commitment to advancing GEO-CM04S1 remains unwavering. This next-generation, multi-antigen COVID-19 vaccine is highly differentiated and continues to show promise, particularly for the over 40 million immunocompromised individuals in the U.S. who remain vulnerable to current variants. Our ongoing Phase 2 trials, including studies in chronic lymphocytic leukemia patients and stem cell transplant recipients, are progressing well, with key data readouts anticipated in the first half of 2025,\" stated David Dodd, GeoVax's Chairman and CEO.GEO-CM04S1 continues to demonstrate potential as both a primary and boo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-reports-first-quarter-2025-200000871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4232","BK4548","BNTX","R","BK4585","BK4022","GOVX","BK4588","BK4535","GOVXW","BK4568","BK4551","BK4139"],"gpt_icon":0},{"id":"2532388741","title":"Moderna (MRNA) Receives a Hold from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2532388741","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532388741?lang=en_us&edition=fundamental","pubTime":"2025-05-02 03:35","pubTimestamp":1746128121,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $28.00. The company’s sh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/moderna-mrna-receives-a-hold-from-rbc-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/moderna-mrna-receives-a-hold-from-rbc-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","BK4551","BK4139","BK4533","BK4532","BK4534","MRNA","BK4588","BK4207","BK4501","BK4548","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":11,"totalSize":224,"code":"91000000","status":"200"}]}}